DGAP-News: Press Release: 4SC presents results from analysis of biomarkers and prognostic factors in Phase II SHELTER …
DGAP-News: 4SC AG / Key word(s): Miscellaneous Press Release: 4SC presents results from analysis of biomarkers and prognostic factors in Phase II SHELTER trial with resminostat in advanced liver cancer (HCC)
13.09.2013 / 07:30
---------------------------------------------------------------------
Press Release
4SC presents results from analysis of biomarkers and prognostic factors in Phase II SHELTER trial with resminostat in advanced liver cancer (HCC)
- Identification and further characterization of novel potentially predictive biomarker ZFP64 indicative for survival upon treatment with resminostat in patients with advanced HCC
- High baseline expression of ZFP64 in peripheral blood (observed in about 2/3 of patients) correlates with doubling of median overall survival compared to low baseline ZFP64
- Additional patient baseline characteristics influencing overall survival in HCC identified
- Both ZFP64 biomarker analysis and patient baseline characteristics to be integrated for patient stratification in planned pivotal programme with resminostat in advanced HCC
- Oral presentation of detailed results at ILCA conference, 15 Sept. 2013, Washington D.C.